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Abstract
Background: The clinical and pathological characteristics and the clinical course of patients with
breast cancer and BRCA 1–2 mutation are poorly known.
Methods: From 1997, patients with breast cancer and a family history of breast or ovarian cancer
were offered BRCA testing. The clinical and pathological features of patients with known BRCA
status were retrospectively assessed and comparisons were made between cancers arising in
BRCA positive and BRCA wild type (WT) patients respectively. Type of treatment, pattern of
relapse, event (local relapse, contralateral breast cancer, metastases) free and overall survival were
also compared in the two groups. Out of the 210 patients tested, 125 had been treated and
followed-up at our Institution and were evaluated in this study.
Results: BRCA positive patients tended to be more often premenopausal (79% vs 65%) and to
have positive lymphnodes (63% vs 49%), poorly differentiated tumours (76% vs 40% – p = 0.002 at
univariate analysis, not significant at multivariate analysis) and negative estrogen receptors (43% vs
29%). Treatment was not different in the two groups. In the 86 BRCA-WT patients, the first event
was a local relapse in 3 (3%), metachronous contralateral breast cancer in 7 (8%) and distant
metastases in 16 (19%). In the 39 BRCA positive patients, the corresponding figures were 3 (8%),
8 (21%) and 3 (8%). There was no difference in event free survival, with a median of 180 months in
both groups of patients. At 20 years, projected survival was 85% for BRCA positive patients and
55% for BRCA-WT, but this difference was not statistically significant.
Conclusion: Although BRCA positive patients have more frequently negative prognostic factors,
their prognosis appears to be equal to or better than in patients with BRCA-WT.
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Background
The issue of familial breast cancer has raised much atten-
tion in recent years due to its numerous medical and
social implications. Following to the identification of the
tumour suppressor genes BRCA1 and BRCA2 and of the
increase in breast cancer risk associated with mutations of
these genes, several studies have examined the entity of
this risk and the diagnostic and therapeutic procedures
indicated to curtail the incidence of breast and ovarian
cancer in this population [1].
Whether the cases of breast cancer arising in BRCA1-2
positive women are different from those occurring in the
general population in terms of biologic characteristics,
response to treatment and eventual outcome has not been
fully elucidated, although most reports suggest that
BRCA1-2 positive cases differ from sporadic cases without
familiarity for more frequent adverse prognostic factors
[2].
At our Institution, a programme of identification of
healthy BRCA1-2 carriers is ongoing, starting with the
determination of the BRCA status in patients with breast
cancer and a significant family history. This caused the
identification of a population of breast cancer patients
with family history, with or without BRCA1-2 mutation.
With the aim of ascertaining the differences in the clinical
and pathological characteristics and in the clinical course
of these two groups of patients, we retrospectively evalu-
ated and compared several clinico-pathologic and thera-
peutic issues and the outcome of patients with or without
BRCA1-2 mutation.
The results of that study are the subject of the present
report.
Methods
From 1997, patients with breast cancer presenting at our
Institution were considered for eligibility to BRCA testing.
Conditions of eligibility included a history among first
degree relatives of: at least two cases of breast cancer <50
years; or at least 3 cases of breast cancer, any age; or at least
two cases of bilateral breast cancer, any age; or at least two
cases of ovarian cancer, any age; or at least one case of
breast cancer <50 years plus one case of ovarian cancer,
any age. Eligible patients were offered BRCA testing and
consenting patients underwent genetic testing according
to standard methods. In case of a positive test, genetic test-
ing was also offered to healthy first degree relatives.
The clinical and pathological features of patients with
known BRCA status were assessed and comparisons were
made between cancers arising in BRCA positive and BRCA
wild type (WT) patients respectively. Type of treatment,
pattern of relapse, event (local relapse, contralateral breast
cancer, metastases) free and overall survival were also
compared in the two groups. In case of bilateral meta-
chronous breast cancer, the primary tumour was consid-
ered to be the index cancer and the secondary tumour was
classified as an event (contralateral breast cancer). Overall
and progression free survival curves were estimated by the
Kaplan-Meier technique and compared with the use of the
two-sided log-rank test. The Cox proportional hazards
model was fittted to assess the association with selected
patient characteristics. The model included also terms for
age (one-year age group) and tumour grade. A p value of
less than 0.05 was required to reject the null hypothesis.
Out of the 210 patients tested, 125 had been treated and
followed-up at our Institution and were evaluated in this
study.
Results
Of the 125 patients with known BRCA status followed or
treated at our Institution, 86 were BRCA-WT and 39 were
BRCA positive (9 BRCA1, 30 BRCA2). The main character-
istics of the patients at the time of diagnosis of breast can-
cer and the primary treatment received are reported in
Table 1. BRCA positive patients tended to be more often
premenopausal (82% vs 64%) and to have positive lym-
phnodes (63% vs 49%), poorly differentiated tumours
(76% vs 40% – p = 0.002 at univariate analysis, not signif-
icant at multivariate analysis)) and negative oestrogen
receptors (43% vs 30%). BRCA-WT tended to be more
often multifocal or multicentric (47% vs 33%). Only a
minority of patients had a HER-2 determination. Previous
treatment was not different in the two groups, although,
as expected from oestrogen receptors distribution, more
BRCA-WT patients received adjuvant hormone therapy
and more BRCA positive patients received adjuvant chem-
otherapy. Although numbers were small, there was no sig-
nificant difference between BRCA1 and BRCA2 cases. In
the 30 BRCA2 cases, average age was 40.3 years, 62% of
patients were premenopausal, 7% had T3-T4 tumours,
67% were node positive, 69% had G3 and 29% oestrogen
receptor negative tumours.
The median follow-up time was 69 months (range, 10–
280 months). In the 86 BRCA-WT patients, the first event
was a local relapse in 3 (3%), metachronous contralateral
breast cancer in 7 (8% of the 84 patients with primary uni-
lateral breast cancer) and distant metastases in16 (19%).
In the 39 BRCA positive patients, the corresponding fig-
ures were 3 (8%), 8 (21% of the 38 patients with primary
unilateral breast cancer) and 3 (8%). The difference in the
frequency of contralateral breast cancer as first event
approached statistical significance (p = 0.07).BMC Cancer 2005, 5:70 http://www.biomedcentral.com/1471-2407/5/70
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Event free survival in BRCA-WT and BRCA positive
patients is shown in Figure 1. There was no difference in
event free survival, with a median of 180 months in both
groups of patients. Overall survival is shown in Figure 2.
At 20 years, projected survival was 85% for BRCA positive
patients and 55% for BRCA-WT, but this difference was
not statistically significant. There was no difference in
event free survival and overall survival between BRCA1
and BRCA2 positive patients.
Discussion
Although the importance of family history as a risk factor
for breast cancer is widely recognized, there is disagree-
ment on its impact upon prognosis, with conflicting
results reported in several series [3,4]. The discovery of the
breast cancer susceptibility genes BRCA1-2 has allowed a
clearer identification of genetically related cases.
Some studies suggest that mutations of the BRCA gene
may be related, besides their impact on the susceptibility
to breast and ovarian cancer, to distinctive biological char-
acteristics and clinical course.
In general, the histopathologic features of BRCA associ-
ated cases are reported as being more unfavourable as
compared to sporadic cases, with more high-grade, oestro-
gen receptor negative and rapidly proliferating tumours
[5]. In a recent study, nodal status was found to be corre-
lated with tumour size in BRCA-1 negative but not in
BRCA-1 positive patients [6]. In some relatively small
studies, the prognosis of patients with BRCA mutations
was worse [7-9] or comparable [10,11] to that of sporadic
cases. In these series, prognostic factors were generally
worse than in sporadic cases. In a Finnish study [12], it
was noted that BRCA1 breast cancer patients had a lower
survival rate than sporadic cases, BRCA2 patients or
patients with non BRCA1/2 related familial breast cancer.
However, the difference was not statistically significant. It
should be noted that the BRCA positive patient popula-
tions studied varied much, including Ashkenazi Jewish
patients with node negative disease [7], early-onset dis-
ease [8,9], or familial breast cancer [11,12]. Also control
groups were different, varying from BRCA negative cases
in the same population to large population based regis-
tries. The clinical implications of these findings appear
not to be fully understood and more data on the issue are
necessary before conclusions can be drawn. In particular,
the impact of BRCA alterations upon survival is unclear
[13].
In the present series, we analyzed the clinical characteris-
tics, treatment and outcome in a group of patients with
familial breast cancer according to their BRCA status.
The first finding to be mentioned is that, even in a group
of breast cancer with a family history, the incidence of
BRCA mutations is relatively low (about 25%) in our pop-
ulation of Italian women. This further stresses the need for
stringent selection criteria before offering the test to the
individual women. Besides, as a consequence, the study
population was not large enough to detect small differ-
ences between BRCA positive and negative case..
The characteristics of patients differed in the two groups,
in that features linked to an aggressive course (premeno-
pausal status, poorly differentiated tumours, ER negative,
node positive) were or tended to be more frequent in
Table 1: Patient Characteristics and their corresponding hazard ratios*
CHARACTERISTICS OF 
PATIENTS
BRCA-WT (n = 86) BRCA+ (n = 29) p-value# Hazard Ratio (95% CI)
Average age in years (range) 45.3 (22–82) 42.3 (26–62) _ _
Laterality (right/left/bilat)+ 35/41/5 15/13/1 0.68 1.3 (0.1–5.7)
Premenopausal 53/81 (65%) 23/29 (79%) 0.17 1.9 (0.5–6.7)
T3-T4 8/83 (10%) 3/23 (13%) 0.64 1.2 (0.3–6.5)
N+ 37/76 (49%) 17/27 (63%) 0.20 1.4 (0.5–4.6)
G3 31/77 (40%) 19/25 (76%) 0.002 2.6 (0.8–7.2)
Multifocal-multicentric 38/82 (46%) 8/24 (33%) 0.26 0.8 (0.1–3.7)
ER- 20/70 (29%) 10/23 (43%) 0.18 1.5 (0.4–5.1)
Pgr- 22/72 (31%) 8/23 (35%) 0.71 1.1 (0.2–6.7)
HER2 2+/3+ 11/31 (35%) 2/13 (15%) 0.18 0.6 (0.02–4.9)
*analyses stratified according to age (one-year age group) and tumour grade
# univariate chi-square
+ Hazard Ratio not computed for bilateralityBMC Cancer 2005, 5:70 http://www.biomedcentral.com/1471-2407/5/70
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BRCA (predominantly BRCA2) positive patients. Treat-
ment was similar.
The first event was more frequently distant metastases in
BRCA-WT patients and contralateral breast cancer in
BRCA positive patients. Time to progression was
superimposable.
When survival curves are examined, one should take into
account that the mechanism of the study caused long sur-
vivors to be overrepresented, which translates into very
high long term survival rates (median survival has not
been reached at 20 years). It appears that, while event free
survival is superimposable, the percentage of long term
survivors is higher among BRCA positive patients. This
would be in accordance with a protective effect of BRCA,
which counteracts the unfavourable prognostic factors
associated with BRCA positivity. No difference emerged in
our series between BRCA1 and BRCA2 positive patients,
but the small number of BRCA1 cases in this predomi-
nantly BRCA2 series precludes conclusions. These find-
ings are not entirely comparable with most data reported
so far, in that in our series all patients had a family history
of breast cancer and patients with BRCA-WT were proba-
bly positive for other unknown mutated genes. This is in
agreement with a possible protective effect of BRCA posi-
tivity even within otherwise genetically related breast
cancer.
Conclusion
In conclusion, in this series it appeared that BRCA status
interacted with known prognostic factors in determining
the eventual outcome.
Event free survival Figure 1
Event free survival.
BRCA+
BRCA-WT
Log-rank test=0.17; p=0.68
Hazard Ratio
*=0.9; 95% CI:0.2-5.3
*Analysis stratified according to age (one-year age group) and tumour gradeBMC Cancer 2005, 5:70 http://www.biomedcentral.com/1471-2407/5/70
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Whether BRCA may become a clinically useful prognostic
or predictive factor can be ascertained only by large rand-
omized trials. Prospective correlations within ongoing
randomized studies of family history and BRCA status
with outcome appear to be warranted.
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